Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy

Chunshui Liu(First Hospital of Jilin University), Sujun Gao(First Hospital of Jilin University)

Oncology Reports

June 11, 2019

10.3892/or.2019.7194

Cited by 10

Related Papers

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

|The Lancet Oncology|2023|55